DALLAS, TX—Spark Biomedical develops a topical, minimally invasive medical device for alleviating opioid withdrawal symptoms. AcuityMD has a platform for helping medical device companies accelerate commercial access to their products.

In October 2022, Spark and AcuityMD announced a partnership that could provide a pathway to sobriety to millions suffering from opioid addiction. The FDA-approved Sparrow therapy system represents a drug-free tool for helping treat opioid use disorder. It sends mild electrical impulses to the brain to help alleviate withdrawal symptoms.

AcuityMD’s data-driven commercial platform supports this expansion effort. 

“We saw an opportunity in using the AcuityMD platform to ensure that we’re getting the right device in front of the right provider that serves the right patients at the right time,” said Spark Biomedical CCO Dan Wagner, speaking to MassDevice at last month’s The MedTech Conference. “When we’ve done that, it’s phenomenal.”

Read more about The Sparrow therapy system here.